Alturas Analytics, Inc. employee Andrew Taylor is attending the PBSS-Boston Workshop on IND Filing and Nonclinical Considerations for Emerging Modalities: Protein Degraders, Oral Peptides, and Oligonucleotide next week in Cambridge.
Public source
Publisher name
Public post
Andrew Taylor is looking forward to attending the PBSS-Boston Workshop, "IND Filing and Nonclinical Considerations for Emerging Modalities: Protein Degraders, Oral Pepti…
Company
Alturas Analytics, Inc.
"Your Partner in Success"
- Industry
- Biotechnology
- Location
- Moscow, US
- Company size
- 51–200 employees
About Alturas Analytics, Inc.
At Alturas Analytics, we deliver results on time with the highest level of integrity. Our business is built on developing long term collaborations with our clients by providing advanced MS/MS solutions through a focused emphasis on teamwork, communication and exceptional science. Alturas has a proven record with complex analysis supporting drug candidates for the pharmaceutical and biotechnology industries, from discovery through phase IV clinical trials. The company operates in a GLP environment using validated operational processes in strict adherence to internal SOPs and applicable global regulations. Bioanalytical services routinely performed include the following: • GC-MS/MS and LC-MS/MS bioanalysis – allows for the broadest range of chemical properties across a wide mass range • GLP and non-GLP bioanalysis of large and small molecules in any matrix • Quantitative Antibody Drug Conjugates (ADC) analysis • Biomarker quantitation • Protein binding estimations • Dried Blood (DBS) and Matrix Spot (DMS) analysis (limited sample volume ex. pediatrics, CSF, tears) Ensuring that a project is completed on time to a company's specifications demands clear lines of communication before, during, and after a study's completion. Clients have direct access to a team of professionals who understand the critical nature of the business. An Alturas Study Director is assigned to each client based on their working knowledge with compounds of similar chemical properties. Comments & Feedback: "Thanks. We owe a lot to Alturas for the great nonclinical and clinical bioanalytical support for the program. Happy 2013!" January 2013: Comment from a Sponsor after receiving FDA Approval. “You solved all of our bioanalytical problems.” Comment from a Sponsor after the Alturas Team was able to address technical difficulties. "Five Stars. Would definitely use Alturas again for upcoming projects." Comment from a Sponsor in 2016.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Apertura Gene Therapy
Apertura Gene Therapy employee Jorge Santiago-Ortiz, Ph.D., is attending the 2026 Advanced Therapies Europe Conference in Barcelona.
Presence & Recognition
Artis BioSolutions
Artis BioSolutions is attending the Advanced Therapies Europe event in Barcelona from September 7-9 at the InterContinental.
Presence & Recognition
BioAscent
BioAscent Senior Scientist David Robinson will attend the 10th RSC BMCS Fragment-based Drug Discovery Meeting in Cambridge next week.
Presence & Recognition
NewBiologix
NewBiologix is attending the Advanced Therapies Europe 2026 conference in Barcelona.
Presence & Recognition
X-Therma Inc.